Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice.
Aline David-SilvaJoão Victor EstevesMychel Raony P T MoraisHelayne Soares FreitasTelma Maria ZornMaria Lucia Correa-GiannellaUbiratan Fabres MachadoPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
NAFLD accompanies altered hepatic glucose metabolism in T2D mice and that greatly ameliorated through short-term treatment with the dual SGLT1/2 inhibitor. This suggests that altered hepatic glucose metabolism participates in T2D-related NAFLD and highlights the pharmacological inhibition of SGLTs as a useful approach not only for controlling glycemia but also for mitigating development and/or progression of NAFLD.
Keyphrases